期刊
JOURNAL OF CONTROLLED RELEASE
卷 346, 期 -, 页码 317-327出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2022.04.030
关键词
Ultrasound; Molecular imaging; PDL1; Cancer imaging; Nanobubbles
资金
- Department of Radiology, Stanford University
PD-L1 targeted therapies may be effective for various cancers. Non-invasive diagnostic and prognostic molecular imaging platforms can enhance clinical assessment of PD-L1 tumor status. By utilizing ultra-stable nanobubbles as a contrast agent, functionalized with nanobody targeting human PD-L1, molecular imaging of the tumor is possible. The results showed a three-fold increase in contrast signal compared to non-targeted nanobubbles. This research has the potential for clinical translation and prognostic evaluation of patient response to PD-L1 targeted immunotherapy.
PD-L1 (programmed death-ligand 1) targeted therapies may be useful for several cancers. The use of non-invasive diagnostic and prognostic molecular imaging platforms could improve clinical assessment of PD-L1 tumor status during these therapies. Contrast enhanced ultrasound molecular imaging (CE-USMI) techniques may offer versatile and cost-effective ways to detect and quantify the expression levels of cellular targets in vivo. However, conventional use of microbubbles as a blood pool contrast agent for CE-USMI is limited to accessing intravascular biomarkers rather than reflecting the tumor molecular status. Using a microfluidic based reconstruction process we therefore developed ultra-stable nanobubbles (NBs) as a contrast agent for molecular imaging of vascular and extravascular cell surface markers. We then functionalized these NBs by covalently linking to nanobody (FN3hPDL1) targeting human (h)PD-L1 to measure the expression of human PD-L1 in the tumor microenvironment (TME) in vivo. We showed the specific binding of hPD-L1 targeted NBs in cell culture, and in xenografted mouse models of hPD-L1 expressing CT26 tumors. CE-USMI of hPD-L1 in the TME in vivo showed ~3-fold increase in contrast signal compared to non-targeted NBs. Overall, in vivo use of CE-USMI with hPD-L1 targeted NBs has the potential for clinical translation and imaging of human cancers during immunotherapy, and for prognostic evaluation of patient response to PD-L1 targeted immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据